A significant challenge in the oncology domain is posed by resistance to osimertinib in HER2-positive tumors.Osimertinib, as a potent EGFR TKI, has shown remarkable efficacy in treating individuals with NSCLC (NSCLC).However, its long-term efficacy has been limited by the development of resistance mechanisms.The aim of this article is to explore the various aspects of resistance to osimertinib in HER2-positive tumors, including the fundamental mechanisms, possible treatment approaches, and current research endeavors.Various mechanisms can lead to resistance to osimertinib in HER2-positive tumors.One primary mechanism involves the gaining of additional mutations in…
